Immune checkpoint inhibitors (ICIs) block immune checkpoints on the surface of tumor cells, such as Programmed Death Protein 1 (PD-1) and its ligand PD-L1, thereby enhancing the body’s anti-tumor immune response. The gene discussed is CD274; the disease is neoplasm.